Skip to main content
NurExone Biologic Inc logo

NurExone Biologic Inc — Investor Relations & Filings

Ticker · NRX ISIN · CA67059R1091 LEI · 25490047UWNZ2P8ESB77 TSXV Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2025-06-06 Governance Information
Country CA Canada
Listing TSXV NRX

About NurExone Biologic Inc

https://nurexone.com/

NurExone Biologic Inc. is a biopharmaceutical technology company specializing in the development of regenerative exosome-based therapies for Central Nervous System (CNS) injuries. The core of its business is the proprietary ExoTherapy platform, which utilizes nanosized extracellular vesicles (exosomes) as precision biological messengers and drug delivery vehicles. These exosomes are loaded with therapeutic compounds, creating nanodrugs designed to target inflamed or damaged neural tissue. A key product candidate is ExoPTEN, an siRNA sequence loaded onto exosomes, which has shown promise in regenerating and rewiring neurons in preclinical models of fully transected spinal cords. The company employs proprietary 2D and 3D production processes within its dedicated in-house bioreactor to ensure high-quality, large-scale production of potent exosomes.

Recent filings

Filing Released Lang Actions
Other.pdf
Governance Information Classification · 72% confidence The document is the full text of an “Amended and Restated Omnibus Incentive Plan,” containing detailed governance rules for issuing options, RSUs, and restricted shares, definitions of committees, board discretion, and other plan governance provisions. It is not an earnings release, proxy solicitation, voting results, or financial report, but rather an internal governance/compensation scheme document. Thus, the most appropriate category is Governance Information (CGR).
2025-06-06 English
News release - English.pdf
Regulatory Filings Classification · 70% confidence The document is a corporate press release announcing new manufacturing process validation data for ExoPTEN and stating that the company will seek shareholder approval of its amended and restated omnibus plan at its upcoming annual general and special meeting. It is not an earnings release (no financial results), not a full annual or interim report, nor a formal proxy statement (the circular itself is separate). It does not fall under specific categories like director dealings, dividends, or M&A. As a general regulatory news announcement (SEDAR/OTCQB press release), it best fits the fallback category of a Regulatory Filing (RNS).
2025-06-04 English
News release - English.pdf
Regulatory Filings
2025-05-30 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a management-solicited proxy form for the Annual and Special Meeting on June 18, 2025, providing instructions on appointing a proxyholder, voting methods, and resolutions to be voted on. This is clearly a solicitation of votes and associated information for a shareholder meeting, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2025-05-28 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a “Notice of Annual and Special Meeting” with detailed voting/proxy instructions and reference to a management information circular. It is clearly pre-meeting proxy solicitation material sent to shareholders to provide information and request votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2025-05-28 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is the combined notice of the annual and special shareholders’ meeting along with the management information circular which solicits proxies, provides detailed background on agenda items (election of directors, auditor re-appointment, amendments to articles, omnibus plan, etc.), and instructs shareholders on voting procedures. This is a classic Proxy Solicitation & Information Statement, not the actual AGM presentation, financial report, or simply an announcement of a report’s publication.
2025-05-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.